## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 1 OF 1

		PTO/SB/08 Equivalent
	Application No.	10/527,430
	Filing Date	March 9, 2005
	First Named Inventor	Bibbs, et al.
	Art Unit	1617
	Examiner	Betton, Timothy E.
	Attorney Docket No.	DIAKR.007NP

			U.S. PATENT	DOCUMENTS	
Examine Initials	Cite No.				

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	EP 0204317	12-10-1986	E.R. Squibb & Sons, Inc.	English equivalent of Japanese Patent No.: 2268180A	
	2	EP 0237347	09-16-1987	E.R. Squibb & Sons, Inc.	English equivalent of Japanese Patent No.: 62265271A	
	3	WO 97/21687	06-19-1997	Merck & Co., Inc.	English equivalent of Japanese Patent No.: 2000501734T	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>		
	4	Atwal, et al., "Dihydropyrimidine Calcium Channel Blockers. 3 3-Carbamoy1-4-aryl-1,2,3,4-tetrahydro- 6-methy1-5-pyrimidincearboxylic acid eaters as orally effective antihypertensive agents" <i>J. Medical</i> Chem. (1991) 43(2):			
	5	Schnell, et al., "Synthesis of enantiomerically pure 4-aryl-3,4-dihydropyrimidin-2(1H)-ones via enzymatic resolution: preparation of the antihypertensive agent (R)-SQ 32926" Tetrahedron: Asymmetry (2000) 11(7): 1449-1453.			
	6	Sundan, "Biginelli' compounds as potent mimics of dihydropyridines" <i>J. Indian Chem. Society</i> (1991) 34(2): 806-811.			

9108687/SRL 052610

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.